Recombinant Chimeric Western and Eastern Equine Encephalitis Viruses as Potential Vaccine Candidates  by Schoepp, Randal J. et al.
Virology 302, 299–309 (2002)Recombinant Chimeric Western and Eastern Equine Encephalitis Viruses
as Potential Vaccine Candidates
Randal J. Schoepp,*,†,1 Jonathan F. Smith,* and Michael D. Parker*
*Virology Division and †Diagnostic Systems Division, United States Army Medical Research Institute of Infectious Diseases,
Fort Detrick, Frederick, Maryland 21702
Received October 30, 2001; returned to author for revision February 26, 2002; accepted July 8, 2002
Chimeric cDNA clones, pMWE1000 and pMWE2000, differing by five nucleotides at their 5 termini, were constructed of
the 5 two-thirds of the western equine encephalitis (WEE) virus genome (encoding nonstructural proteins) and the 3
one-third of the eastern equine encephalitis (EEE) virus genome (encoding structural proteins). The WEE virus sequences
were derived from full-length cDNA clones, pWE1000 and pWE2000, which were isogenic except for five nucleotide
differences at their 5 termini and were responsible for significant differences in mouse virulence. Each cDNA clone was
placed downstream from a T7 promoter to allow in vitro transcription of full-length RNA. Transfection of BHK-21 cells with
the chimeric RNA by electroporation gave rise to high-titer infectious virus. The in vitro characteristics of each chimera virus
were determined by electrophoretic analysis of its structural proteins, plaque morphology, neutralization characteristics,
replication kinetics, and rate of viral RNA synthesis. With the exception of plaque morphology, the in vitro characteristics of
MWE1000 and MWE2000 were indistinguishable from the parental EEE virus. Subcutaneous inoculation of 5-week-old
C57BL/6 mice with varying doses of MWE1000 or MWE2000 virus demonstrated that both chimeric viruses were significantly
attenuated compared to the parental WEE virus (Cba 87) and EEE virus (PE-6). Animals infected with 105 PFU or more of
either MWE1000 or MWE2000 were completely protected from lethal challenge with the virulent EEE virus, FL91-4679, but
were not protected from virulent WEE virus Cba 87 challenge. Construction of viable virus chimeras often results in
attenuated viruses that may hold promise as genetically engineered alphavirus vaccine candidates (R. J. Kuhn, D. E. Griffin,INTRODUCTION
The Alphavirus genus of the family Togaviridae con-
sists of 27 different arthropod-borne viruses and sub-
types (Schlesinger and Schlesinger, 1996). Alphaviruses
are maintained in a natural cycle by mosquito transmis-
sion of virus from infected to susceptible birds or small
rodents. Humans may become infected when they enter
areas in which this sylvatic cycle is occurring and are
bitten by an infected mosquito. The consequences of
human infection range from asymptomatic infection to
severe disease.
Eastern (EEE), western (WEE), and Venezuelan equine
encephalitis (VEE) viruses are three New World alphavi-
ruses known to cause encephalitis in humans and
equines in epidemic proportions. Eastern equine en-
cephalitis virus causes the most severe of the arboviral
encephalitides in humans, with 50 to 75% mortality and
severe neurologic sequelae in survivors (Johnston and
Peters, 1996). The virus occurs primarily along the Atlan-
1 To whom correspondence and reprint requests should be ad-
dressed at Diagnostic Systems Division, 1425 Porter Street, Fort De-299tic and Gulf coasts of North America, but can also be
found in southern Canada and northern South America
and the Caribbean. In enzootic areas of North America,
the natural cycle involves the mosquito Culiseta mela-
nura and passerine birds as amplifying hosts (reviewed
in Scott and Weaver, 1989). In epidemics, Aedes and
Coquillettidia species may bridge the gap between in-
fected birds and humans. The recent advances of the
mosquito Aedes albopictus into North America and its
competence as a vector of EEE virus has increased the
potential for more frequent and widespread epidemics
and enzootics (Mitchell et al., 1992). Western equine
encephalitis virus occurs throughout western North
America and discontinuously in South America to Argen-
tina. In the United States, WEE virus circulates between
the mosquito vector, Culex tarsalis, and wild birds as
reservoir hosts. Phylogenetic analyses determined that
WEE virus is a naturally occurring recombinant of an
EEE-like and Sindbis-like virus ancestor (Hahn et al.,
1988; Levinson et al., 1990; Weaver et al., 1993, 1997).
The alphaviruses as a group are well-characterized
biochemically and antigenically (Strauss and Strauss,
1994). Their RNA genomes are single-stranded, positive-K. E. Owen, H. G. M. Niesters, and J. H. Strauss, 1996, J. V
Key Words: western equine encephalitis; eastern equine
trick, MD 21702-5011. Fax: (301) 619-2492. E-mail: randal.schoepp@
amedd.army.mil.
doi:10.1006/viro.2002.1677, 7900–7909).
alitis; alphavirus; chimera; cDNA infectious clone; vaccine.
sense, and are capped and polyadenylated. Therefore,
viral RNA is infectious when transfected into a suscep-irol. 70
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tible cell. Four nonstructural proteins are translated as a
polyprotein from the 5 two-thirds of the full-length 42S
messenger RNA and serve as the viral replicases and
transcriptases. Three structural proteins, C, E2, and E1,
are translated from a 26S subgenomic messenger RNA
transcribed from the 3 one-third of the genome. The
RNA genome is surrounded by an icosahedral nucleo-
capsid composed of monomers of the C protein. The
nucleocapsid is surrounded by a host-derived lipoprotein
envelope into which the viral glycoproteins, E1 and E2,
are inserted and anchored. The glycoproteins are the
targets of neutralizing antibodies and are the proteins
that mediate interactions with cellular receptors.
Live-attenuated viral vaccines, while not without prob-
lems, are generally considered to be the most successful
viral vaccines. For EEE virus, no live virus vaccine is
available. The current vaccines for human use and vet-
erinary applications are inactivated products that have
low immunogenicity and require multiple inoculations
and periodic boosters to provide adequate protection. A
live-attenuated vaccine for EEE would offer significant
advantages for both human and veterinary use. Recently,
with the development of cDNA clones of various alpha-
viruses (Rice et al., 1987; Davis et al., 1989; Liljestrom et
al., 1991), genetically engineered, multiply attenuated,
live alphavirus vaccines have been proposed (Davis et
al., 1991, 1995). The objective to our research was to
describe the construction of full-length cDNA chimeric
clones of WEE and EEE virus and to characterize the
resulting chimeric viruses in cell culture and mice.
RESULTS
Chimeric virus constructs
The pMWE chimeric virus clones were constructed
from two full-length cDNA clones of WEE virus, pWE1000
and pWE2000, and the cloned structural gene region of
EEE virus (Fig. 1). These chimeric clones, designated
pMWE1000 and pMWE2000, were isogenic except for
five changes in the first 25 nucleotides at the 5 termini
(Fig. 2A). In the WEE parental clones, the five nucleotide
changes engineered into the 5 nontranslated region
(NTR) of the virulent virus WE2000 resulted in a highly
attenuated virus WE1000 (Shoepp and Parker, unpub-
lished data). The differences in the virulence phenotypes
between WE1000 and WE2000 prompted the use of both
WEE virus nonstructural backbones to construct two
different chimeric viruses, MWE1000 and MWE2000 vi-
ruses, which could have different virulence phenotypes
and different immunogenicities.
Using the unique BlnI restriction site in the C gene of
both the WEE and the EEE genomic clones, we con-
structed two chimeric clones containing the nonstruc-
tural protein domain of WEE virus and structural protein
FIG. 1. Construction of the WEE virus full-length clones, pWE1000 and pWE2000. PCR fragments were produced using specific WEE virus
oligonucleotide primer pairs. Convenient restriction enzyme sites were used to assemble two cassettes: pWE5-18 representing the 5 genomic
sequence and pWE3-17 representing the 3 genomic sequence. Final assembly was accomplished by joining the two cassettes at the unique BlnI
site. Exchange of the 5 terminal sequence from pWE1000 to pWE2000 was done by inserting a new SstII-MluI fragment in the pWE5-18 cassette.
Oligonucleotide primers used to amplify each fragment are in parentheses. Unique restriction enzyme sites and the nucleotide position of each
fragment termini are indicated.
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domain of EEE virus (Fig. 2B). The BlnI restriction site
occurs 76 nucleotides downstream of the EEE virus C
gene start site. Each chimeric clone contained a 7671-bp
cDNA fragment encoding the WEE virus nonstructural
genes, 26S subgenomic promoter, and 76 bp of the C
gene ligated to a 4010-bp EEE cDNA fragment encoding
the remainder of the C gene, the other structural pro-
teins, and the 3 NTR. The chimeric viruses were pro-
duced from the cDNA clones after runoff transcription
from the T7 promoter and transfection of BHK-21 cells.
Viral stocks were prepared and each virus was com-
pared to parental viruses for plaque morphology, struc-
tural protein profile, antibody neutralization, and viral
replication. The plaque size of the chimeric viruses on
Vero cells was substantially smaller than those of either
parental virus, suggesting that viral replication may have
been impaired under these conditions (Table 1). How-
ever, one-step differential growth curves (Fig. 4), mea-
suring the relative rates of virus production in BHK-21
cells, indicated that the chimeric viruses replicated at
essentially the same rate and to the same titer as those
observed for the parental EEE virus, PE-6, but at twice
the rate or more of the WEE viruses. In C6/36 cells, the
rate of virus release was somewhat more variable, but
generally the chimeric viruses replicated similar to the
EEE virus and at rates higher than that of the WEE
viruses. These data indicated that the chimeric viruses,
MWE1000 and MWE2000, were not impaired in their
abilities to replicate in cell culture even though differ-
ences in plaque morphology were extensive.
Viral proteins from purified preparations of chimeric
and parental extracellular virions were analyzed by SDS–
PAGE. BHK-21 cell cultures infected with parental and
chimeric viruses were harvested at 24 h after infection
and virions were pelleted through 20% sucrose cushions.
FIG. 2. Construction of the chimeric viruses, MWE1000 and MWE2000. (A) Sequences at the 5 terminus in chimeric and parental EEE and WEE
viruses. Nucleotides are shown and numbered 5 to 3. A box indicates nucleotides that differ within the group of viruses. A dash is inserted to allow
proper alignment of the sequences for comparison. (B) Derivation of sequences used in the construction of chimeric viruses, MWE1000 and
MWE2000. Each chimera was constructed from the 5 two-thirds of the WEE virus genome (encoding nonstructural proteins) and the 3 one-third of
the EEE virus genome (encoding structural proteins) utilizing a unique BlnI restriction enzyme site 76 nucleotides downstream of the start of the C
gene. Chimera virus MWE1000 also possessed EEE virus sequence at the 5 terminus.
TABLE 1
Neutralizing Antibody Titers of MWE Virus Chimeras and Parental
Viruses after Treatment with Anti-WEE and Anti-EEE Antibodies
Virus
Plaque
morphology
(mm)
80% Plaque reduction
neutralization
antibody titer
Anti-WEE Anti-EEE
EEE, PE-6 2 20 320
MWE1000 0.5 20 160
MWE2000 0.5 20 160
WEE, WE1000 2 80 20
WEE, WE2000 2 40 20
WEE, Cba 87 3 40 20
Vesicular stomatitis Not applicable 20 20
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The protein profiles of the chimeric viruses that pos-
sessed the structural protein genes of EEE virus ap-
peared identical to EEE virus, PE6. In contrast the glyco-
proteins, E2 and E1, and capsid protein, C, of MWE1000
and MWE2000 were distinctly different from the WEE
viruses (Cba 87, WE1000, and WE2000) (Fig. 3).
The antigenic characteristics of the viruses were de-
fined in comparative neutralization tests, which is the
assay used to differentiate alphaviruses (Table 1). Each
chimera and parental virus was plaqued in the presence
of varying dilutions of either anti-EEE or anti-WEE neu-
tralizing antibodies. The two chimeric viral clones, having
the structural proteins of EEE virus, and the parental EEE
virus, PE-6, were neutralized by the anti-EEE neutralizing
antibodies. In contrast, the anti-WEE neutralizing anti-
body had no effect on the chimeric viruses, while it
efficiently neutralized the parental WEE virus, Cba 87,
and the two WEE virus clones, WE1000 and WE2000.
Growth properties of the chimeric viruses
As a measure of chimeric viral replication efficiency,
one-step differential growth curves were prepared and
compared to that of the parental viruses (Kuhn et al.,
1991, 1996). Growth curves for chimeric and parental
viruses were prepared in two different cell lines: a mam-
malian cell line, BHK-21, and an Ae. albopictus mosquito
cell line, C6/36. In general, chimera virus replication in
BHK-21 and C6/36 cells was comparable to or better than
the replication of the parental viruses. Initially in BHK-21
cells, the chimeric viruses grew at similar rates to both
the EEE and the WEE parental viruses (Fig. 4A). However,
by conclusion of the 12-h study, the chimeric viruses,
MWE1000 and MWE2000, were replicating at about one-
half the rate of EEE virus, but at rates two- to threefold
higher than the rate of WEE viruses.
In C6/36 cells, growth rates of the chimeric and pa-
rental viruses varied more than in BHK-21 cells (Fig. 4B).
Early in the infection [3 h postinfection (p.i.)], all the
viruses were at similar levels. By 7 h p.i., viruses began
to segregate into two groups, a higher production group
composed of the parental EEE virus, PE-6, and the two
chimeric viruses, MWE1000 and MWE2000; and a lower
production group composed of the WEE viruses, Cba 87,
WE1000, and WE2000. Late in the infection (12 h p.i.), the
chimeric viruses produced virus at a rate equal to or
higher than that of the EEE virus. This rate was higher
(about 10-fold) than that of the WEE viruses, WE1000 and
WE2000, and about twofold higher than that of Cba 87.
Other studies demonstrated that growth of alphavirus
chimeras is more variable in mosquito cells, which tend
to be more sensitive to defects or variations in virus
FIG. 3. SDS–PAGE of MWE chimeras and parental viruses. Viruses
were pelleted through a 20% sucrose cushion and proteins separated
by SDS–PAGE. Proteins were visualized by staining with Coomassie
blue. Lane 1, molecular weight standards: myosin, 200,000; -galacto-
sidase, 116,250; phosphorylase B, 97,400; bovine serum albumin,
66,200; and aldolase, 39,200. Lane 2, EEE virus, strain PE-6; Lane 3,
WEE virus, clone WE1000; Lane 4, MWE1000 clone; Lane 5, WEE virus,
clone WE2000; Lane 6, MWE2000 clone; and Lane 7, WEE virus, strain
Cba 87. E1 and E2 represent the positions of WEE virus glycoproteins.
C represents capsid proteins.
FIG. 4. One-step differential growth curves for the MWE chimeras and parental viruses. Growth curve experiments were performed in BHK-21 cells
at 37°C (A) and in C6/36 mosquito cells at 30°C (B) as described under Materials and Methods. Symbols for each virus appear in the legend to the
right of the graphs.
302 SCHOEPP, SMITH, AND PARKER
growth (Kuhn et al., 1991, 1996; Niesters and Strauss,
1990a,b).
RNA synthesis
We examined RNA synthesis by the chimeric and pa-
rental viruses as another measure of viral replication
efficiency. BHK-21 and C6/36 cells were infected with the
respective virus and labeled with [3H]uridine 2 h p.i. At
various times, cells were harvested and lysed, and the
amount of incorporation determined. This assay deter-
mined the total cumulative [3H]uridine incorporation
compared to the rate of virus release. RNA synthesis by
the chimeric and parental viruses in BHK-21 cells was
essentially equal throughout the 12-h study (Fig. 5A). At
4 h p.i., RNA synthesis was near maximum and in-
creased little until the conclusion of the study. Similarly,
in C6/36 cells RNA synthesis of the chimeric and paren-
tal viruses was equal (Fig. 5B). However, RNA synthesis
in C6/36 cells lagged behind BHK-21 cells and maximum
synthesis was not reached until 5 h p.i. After 6 h, the RNA
synthesis declined slightly until the conclusion of the
study.
Vaccination studies
Five-week-old female C57BL/6 mice were inoculated
subcutaneously with the two chimeric viruses, MWE1000
and MWE2000, and the parental viruses, EEE virus (PE-6)
and WEE (Cba 87) cloned viruses, WE1000 and WE2000.
Animals were monitored for 21 days for mortality and
mean day to death (MDD) was calculated. Both chimeric
viruses were significantly attenuated, causing only spo-
radic deaths in vaccination groups receiving the higher
doses of virus (Table 2). No deaths occurred in the
vaccination groups inoculated with 103 PFU of either
chimeric virus. Of the mice inoculated with 105 PFU of
MWE1000 or MWE2000, each killed 2 of 20 mice. The two
vaccination groups had similar MDD values of 10.5 and
8.0 days, respectively, that were similar to those of the
parental viruses, PE-6 and WE2000. Only one mouse
inoculated with 107 PFU of MWE2000 died at 16 days p.i.
and no deaths occurred in the similar MWE1000 vacci-
nation group. Our findings suggest that the chimeric
viruses were significantly attenuated, causing mortality
in 10% or less animals, when inoculated subcutaneously.
This is in contrast to the more virulent parental EEE virus
strain, PE-6, and WEE virus molecular clone of Cba 87,
WE2000, which produced mortality rates in mice of 70
and 100%, respectively.
The significantly attenuated nature of the MWE virus
chimeras (Table 2) and their ability to induce EEE virus
neutralizing antibodies (Table 3) suggested that surviving
animals may have been protected from challenge by a
virulent EEE virus. To test this hypothesis, animals vac-
cinated with MWE1000 or MWE2000 viruses were chal-
lenged intraperitoneally with a lethal dose of virulent EEE
virus, FL91-4679, or parental WEE virus, Cba 87. As con-
trols, the animals inoculated with HBSS diluent as mock-
vaccinated controls in the study above were divided into
two groups and inoculated with the challenge viruses.
FIG. 5. RNA synthesis by the MWE chimeras and parental viruses. RNA synthesis experiments were performed in BHK-21 cells at 37°C (A) and
in C6/36 mosquito cells at 30°C (B) as described under Materials and Methods. Symbols for each virus appear in the legend to the right of the graphs.
TABLE 2
Infection of C57BL/6 Mice by Subcutaneous Inoculation of Varying
Doses of MWE Virus Chimeras or Parental Viruses
Virus strain
Dose
(PFU per mouse) Mortality (%)
Mean day
to death
(days)
EEE, PE-6 105 7/10 (70) 6.0
WEE, WE1000 105 0/20 (0) NAa
MWE1000 103 0/10 (0) NA
105 2/20 (10) 10.5
107 0/10 (0) NA
WEE, WE2000 105 10/10 (100) 8.5
MWE2000 103 0/10 (0) NA
105 2/20 (10) 8.0
107 1/10 (10) 16.0
HBSSb control None 0/20 (0) NA
a Not applicable.
b Diluent control.
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None of the 8-week-old control mice challenged with
EEE virus survived and mice challenged with WEE virus
resulted in only 30% survival (Table 3).
Of the animals vaccinated with 103 PFU of MWE1000
virus, 50% survived challenge with virulent EEE virus and
responded with low titer postchallenge neutralizing an-
tibodies (Table 3). Ninety percent of the animals vacci-
nated with 105 PFU of MWE1000 survived challenge with
EEE virus and responded with neutralizing antibodies.
The corresponding animals challenged with WEE virus
resulted in 63% survival and produced lower titered
antibodies. All animals inoculated with 107 PFU of
MWE1000 survived challenge and responded with high-
titer EEE virus-neutralizing antibodies.
In general, animals vaccinated with the chimeric virus
MWE2000 responded in a similar fashion to viral chal-
lenge as described for MWE1000 virus. As the vaccine
dose of MWE2000 increased, survival postchallenge in-
creased as did postchallenge neutralizing antibody titers
(Table 3). Of the animals inoculated with 103 PFU of
MWE2000 virus, 60% survived challenge to EEE virus and
responded with high-titer neutralizing antibodies. All of
the animals inoculated with 105 PFU of MWE2000 sur-
vived challenge with EEE virus and responded with neu-
tralizing antibodies. The corresponding animals chal-
lenged with WEE virus resulted in 44% survival and
produced lower titer antibodies. All animals vaccinated
with 107 PFU of MWE1000 survived challenge and re-
sponded with high-titer EEE virus neutralizing antibod-
ies.
DISCUSSION
Two chimeric viruses, MWE1000 and MWE2000, were
derived from full-length cDNA clones containing the 5
two-thirds of the WEE virus genome coding for the non-
structural proteins and the 3 one-third of the EEE virus
genome coding for the structural proteins. The WEE
nonstructural gene regions were derived from two
unique WEE virus clones, pWE1000 and pWE2000, which
were isogenic except for five nucleotide differences in
the 5 NTR. These 5 nucleotide differences produced
viruses that significantly differed in virulence phenotype:
WE1000 was highly attenuated in mice, while WE2000
was highly virulent (Schoepp and Parker, unpublished
data). To evaluate the effect of the 5 nucleotide changes
in the chimeric viruses, we constructed pMWE1000 and
pMWE2000 using the two different WEE nonstructural
gene regions and the same EEE virus structural gene
region (Fig. 2). The two chimeric MWE viruses produced
glycoproteins that were indistinguishable from EEE virus
in vitro and in vivo and were able to infect and replicate
in cell culture as well as either of the parental viruses.
This is in contrast to other chimeric alphaviruses that
were compromised in some fashion by possible incom-
patibilities between heterologous domains or the gene
products they encode. The chimeric viruses may have
reduced RNA synthesis (Kuhn et al., 1991, 1996), reduced
viral replication (Kuhn et al., 1991, 1996), and/or impaired
viral maturation (Lopez et al., 1994; Smyth et al., 1997; Yao
et al., 1996, 1998) as compared to the parental viruses
from which they were derived. However, this was not the
TABLE 3
Challenge of C57BL/6 Mice Immunized with MWE Virus Chimeras or Parental Viruses
Immunogen Dose (PFU per mouse)
Prechallenge neutralizing
antibody titer Challenge virus Percent survival (S/T)a
MWE1000 103 184 EEE FL91-4679 50 (5/10)
ND WEE Cba 87 NDb
2560 EEE FL91-4679 90 (9/10)
105
970 WEE Cba 87 63 (5/8)
3880 EEE FL91-4679 100 (10/10)
107 ND WEE Cba 87 ND
MWE2000 103 5120 EEE FL91-4679 60 (6/10)
105 ND WEE Cba 87 ND
1742 EEE FL91-4679 100 (9/9)
107 538 WEE Cba 87 44 (4/9)
3225 EEE FL91-4679 100 (9/9)
ND WEE Cba 87 ND
HBSS control None NAc EEE FL91-4679 0 (0/10)
20 WEE Cba 87 30 (3/10)
a S/T, survival/total.
b Not done.
c Not applicable.
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case with the MWE viruses. Each viral chimera synthe-
sized RNA and replicated at rates that were virtually
indistinguishable from those of the parental viruses.
Studies of Ross River (RR) and Sindbis (SIN) virus chi-
meras indicate that the reduced vigor of these chimeric
viruses is the result of incompatibilities between struc-
tural proteins and the nonstructural proteins or RNA
sequence elements in the nonstructural gene region
(Kuhn et al., 1996). Phylogenetically, RR and SIN viruses
are two of the more distantly related alphaviruses and
therefore their chimeras presumably have greater incom-
patibilities (Strauss et al., 1984; Faragher et al., 1988;
Kuhn et al., 1996). WEE and EEE viruses are relatively
closely related when comparing the 5 two-thirds of the
genomes that code for the nonstructural proteins (Weav-
er et al., 1993, 1997), but appear less related when
comparing the glycoproteins, E1 and E2 (Hahn et al.,
1988; Levinson et al., 1990; Weaver et al., 1997).
WEE virus is thought to be a naturally occurring re-
combinant virus that arose by two independent recom-
binational events involving an EEE-like and SIN-like vi-
rus. The resulting virus, WEE, has the 5 NTR, nonstruc-
tural proteins, capsid protein, part of E3, and the 3
terminal 80 nucleotides derived from an EEE-like virus
and the remaining glycoproteins, E2 and E1, derived from
a SIN-like virus (Hahn et al., 1988; Levinson et al., 1990;
Weaver et al., 1993, 1997). The MWE chimeric viruses,
which combined the nonstructural genes of WEE virus
and the structural gene region of EEE virus, may more
closely resemble the ancestral EEE-like virus from which
the modern day WEE virus evolved. Therefore, the MWE
virus chimeras may not have many of the incompatibili-
ties that occur with other chimeras derived from less
closely related alphaviruses (Kuhn et al., 1991, 1996). The
recombination event that resulted in WEE virus is esti-
mated to have occurred 1300–1900 years ago, while the
alphavirus lineage emerged from a common ancestor
3000 years ago or more (Weaver et al., 1997). Thus, WEE
virus has had considerably less time to diverge from its
putative EEE-like ancestor. As a result, the nonstructural
and structural viral components in the MWE chimeric
viruses were presumably able to interact more efficiently
structurally and functionally.
The chimeric viruses, MWE1000 and MWE2000, were
both highly attenuated in mice inoculated with as much
as 107 PFU per mouse. This was unexpected as the
cloned WEE viruses from which they were derived,
WE1000 and WE2000, respectively, were so different in
virulence phenotype. WE1000 is highly attenuated in
mice with a log10 LD50 of 6.1, which is in contrast to the
virulent WE2000 with a log10 LD50 of 1.9 (data not shown).
When the chimeric viruses were constructed with their
respective nonstructural gene regions from each of
these cloned viruses, MWE1000 was expected to be
more attenuated in mice than MWE2000 due increased
additive or synergistic attenuating effects conferred by
the 5 NTR mutations of WE1000. In fact, the two chimeric
viruses were equally attenuated and indistinguishable in
all experiments. These findings suggest that the mech-
anisms of the attenuation introduced by combining the
heterologous gene regions of WEE and EEE virus were
sufficient to mask the attenuating effects of the nucleo-
tide changes in the 5 NTR of WE1000.
The chimeric viruses, MWE1000 and MWE2000, were
highly attenuated; however, they caused occasional mor-
tality when inoculated into mice (Table 2). This residual
virulence could be the result of the sensitivity of C57BL/6
mice to alphavirus infection; however, it rendered the
viruses unacceptable as vaccine candidates. We at-
tempted to further attenuate the chimeric viruses by
introducing additional attenuating mutations. Specifi-
cally, we removed the PE2 furin cleavage site in the MWE
chimeric viruses by site-directed mutagenesis (data not
shown). Deleting the furin cleavage site results in viruses
that fail to cleave the precursor protein, PE2, into E3 and
E2. The PE2 cleavage-site deletion and the requisite
second-site suppressor mutations have been incorpo-
rated into several promising candidate vaccine viruses
for VEE and WEE viruses to attenuate and reduce rever-
sion frequencies (Davis et al., 1995; Parker, unpublished
data). Incorporating the cleavage-site deletion mutation
in the attenuated MWE2000 virus resulted in a virus that
had a small plaque morphology, but only replicated to
very low titers (approximately 102 PFU/ml). While the
chimeric viruses did not appear to be impaired in vitro,
adding the cleavage-site deletion mutation and the pre-
sumed second-site suppressor mutations may have re-
sulted in an overly attenuated virus that replicated poorly
in cell culture.
Constructing viable virus chimeras often results in
attenuated viruses and thus may provide a useful ap-
proach for creating genetically engineered alphavirus
vaccine candidates (Kuhn et al., 1996). Flavivirus chime-
ras have also been investigated as possible live-attenu-
ated virus vaccines. Intertypic chimeric dengue (DEN)
viruses of DEN-1/DEN-4 and DEN-2/DEN-4 are able to
immunize monkeys to protect them from homologous
challenge (Bray et al., 1996). Similarly, yellow fever/Jap-
anese encephalitis chimeric viruses are attenuated in
mice and rhesus monkeys, suggesting their use as live-
attenuated human vaccine candidates (Chambers et al.,
1999; Monath et al., 2000). The chimeric viruses,
MWE1000 and MWE2000, demonstrated significantly re-
duced virulence when inoculated into mice. The attenu-
ation of these viruses may have been due to incompat-
ibilities between the WEE and EEE viral components.
However, these incompatibilities did not affect the ability
of the viruses to grow and replicate in cell culture. More-
over, when used to vaccinate animals, these viruses
elicited immune responses to EEE virus sufficient to
protect the animals from a lethal challenge with virulent
strains. However, the residual virulence remaining in the
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chimeric viruses is of concern and must be addressed.
Attempts to further attenuate the viruses by removing the
PE2 cleavage site were unsuccessful. While removing
the cleavage site appeared to overattenuate the viruses,
other less stringent mutations may be incorporated to
eliminate the residual virulence. Theoretically, the atten-
uated phenotype of the MWE viruses was the result of
numerous nucleotide and amino acid changes that al-
tered virus–cell interactions. Therefore, the chimeras
would presumably have little chance of reversion to
virulence, yet would provide many of the advantages of
live virus vaccines.
MATERIALS AND METHODS
Cells and viruses
Viruses were propagated on BHK-21 cell monolayers
maintained in Eagle’s minimal essential medium (EMEM)
containing 10% fetal bovine serum (FBS). C6/36 Ae. al-
bopictus mosquito cell lines were maintained in Singh
mosquito culture medium containing 10% FBS. Virus ti-
trations and plaque-reduction neutralization assays were
performed on Vero cells maintained in EMEM containing
10% fetal bovine serum.
The WEE virus strain, Cba 87, was originally isolated
from the brain of a horse that died during a 1958
epizootic in Cordoba, Argentina (Bianchi et al., 1993). The
virus was passaged 14 times in suckling mice and twice
in BHK-21 cell culture. The EEE virus strain, PE-6, is the
parental virus from which previous and the current inac-
tivated EEE vaccine was derived (Randall et al., 1947;
Bartelloni et al., 1970). The virus used in these studies
was the original PE-6 vaccine seed stock passaged once
in chicken embryo fibroblasts and once in BHK-21 cells.
The EEE virus strain, FL91-4679, was originally isolated
from Ae. albopictus mosquitoes collected in Florida in
1991 (Mitchell et al., 1992) and passaged once in suck-
ling mice, three times in Vero cells, and twice in BHK-21
cells. The viruses WE1000 and WE2000 were derived
from BHK-21 cells transfected with RNA from the full-
length cDNA clones pWE1000 and pWE2000, respec-
tively (Fig. 1).
Polymerase chain reaction (PCR) products
Virus from infected BHK-21 monolayers was pelleted
through a 20% sucrose cushion by centrifugation at
27,000 rpm for 3 h in a SW-28 rotor. Viral RNA was
isolated from virions using TRIzol LS as described by the
manufacturer (Gibco-BRL, Gaithersburg, MD). First-
strand cDNA was synthesized by using the SuperScript II
system (Gibco BRL) and priming with oligo(dT)12–18 and
random hexamers. First-strand cDNA template and virus-
specific oligonucleotide primers were used to produce
PCR products for cloning. The PCR included a mixture of
two thermostable DNA polymerases, one of which (Taq
Extender PCR Additive; Stratagene, La Jolla, CA) pos-
sessed 3–5 exonuclease proofreading activity. Virus-
specific oligonucleotide primers contained unique re-
striction enzyme digest sites for subsequent cloning.
Each reaction contained 20 mM Tris–HCl, pH 8.8, 10 mM
KCl, 10 mM NH4SO4, 2 mM MgSO4, 0.1% Triton X-100, 0.1
mg/ml of bovine serum albumin (BSA), 0.2 mM of all four
dNTPs, and 0.8 mM oligonucleotide primers. To the re-
action were added 5 U each of Taq DNA polymerase and
Taq Extender (Pfu DNA polymerase) and one-tenth vol-
ume of the cDNA first-strand synthesis product. The
reaction conditions were as follows: 94°C for 30 s, 52°C
for 1 min, and 72°C for varying times equal to 1 min/Kb
of product for 35 cycles, and then 72°C for an additional
10 min. After thermocycling, the reactions were held at
4°C until purification. PCR products were purified from
unincorporated nucleotides and incomplete fragments
directly or by gel electrophoresis followed by isolation
using Wizard PCR Preps DNA Purification System (Pro-
mega Corp., Madison, WI). PCR products were cloned
into the TA cloning vector, pCR2.1 (Invitrogen Corp.,
Carlsbad, CA).
Construction of the chimeric western and eastern
equine encephalitis virus cDNA clones
The pMWE cDNA clones were constructed from full-
length cDNA clones of WEE virus and a cassette con-
taining the structural genes of EEE virus. Generally,
genomic RNA was prepared from purified virus by phe-
nol:chloroform extraction and ethanol precipitation.
cDNA representing the entire WEE virus genome was
prepared by PCR using a series of primer pairs (Table 4)
based on partial genome sequences located in Gen-
bank. Each PCR product was cloned into pCRII (Invitro-
gen). Due to the lack of WEE virus 5 terminal sequence,
the initial clone, pWE1000, was constructed with the 5
terminal sequence of EEE virus. For construction of
pWE2000, the 5 terminal sequence of Cba 87 virus was
TABLE 4
Oligonucleotide Primers for Preparation of PCR Products Used in
the Construction of WEE Virus Full-Length Clones, pWE1000 and
pWE2000
CBA/87-T7-Sst2 GTCACCGCGGTAATACGACTCACTATAGATAG-
GGCATGGTATAGAG
WEns1962 TCACCTTATTCTGGAACACATCAG
WEE-11 TGGATCCACAAAGTCCCAACCATCGGAG
WEE-10 TCGGATCCGATGAGAAAATATACGCTCCC
WEE-17 GACTGGATCCGCAAACCAGTCCTGTTCTCAGG
WEE-18 GCATGGATCCAGCATGATCGGAAATGTCTTGTC
WEE-5 TCGGATCCACCGCCAAAATGTTTCCATAC
WEE-3 TCGGGATCCCCGGAACATTTGGC
WEE-2 CTGCTTTTCATGCTGCATGCC
WEE-Not CGATGCGGCCGCTTTTTTTTTTTTTTTTTGAAATT-
TTAAAAAC
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determined by 5-RACE as described by Frohman et al.
(1988) and an exchange of the SstII-MluI was done (Fig.
1). The 5 oligonucleotide primer, CBA/87-T7-Sst2, con-
sisted of an SstII site, the promoter for bacteriophage T7
RNA polymerase followed by one G and 14 nucleotides
of the 5 terminal sequence of Cba 87 and was paired
with WEns1962 and used to amplify the terminal 1.9 kb of
the WEE genome. Clones pWE1000 and pWE2000, rep-
resenting complete genomes, were assembled in pBlue-
script KS (Stratagene) using convenient restriction
sites in the cDNA clones and the plasmid polylinker. To
facilitate construction of the pMWE clones, two cas-
settes representing the WEE 5 genomic 7.6 kb, (pWE5-
18) and the WEE 3 genomic 4.2 kb (pWE 3-17), were
constructed. Full-length WEE clones were assembled by
digestion of pWE5-18 with BlnI and NotI and insertion of
a 4.1-kb BlnI-NotI fragment of pWE 3-17 (Fig. 1).
The full-length cDNA clones, pWE1000 and pWE2000,
from which the chimeric viruses were assembled, were
isogenic except for five nucleotide changes in the 5 NTR
(Fig. 2A). The WEE cDNA clone, pWE1000, was assem-
bled with the first 25 nucleotides of the EEE virus 5
termini. Clone pWE2000 was assembled with an authen-
tic WEE virus 5 termini. The resulting virus WE1000 was
highly attenuated in mice when compared to WE2000
virus; 6.1 versus 1.9 log10 lethal dose 50% (log10LD50). The
EEE virus structural protein gene clone was assembled
from PCR products obtained by using first-strand cDNA
synthesized from EEE virus strain, PE-6, virus-specific
oligonucleotide primers, and Taq DNA polymerase and
Taq Extender PCR Additive (Stratagene). The EEE struc-
tural gene region with the 26S subgenomic RNA pro-
moter was subcloned into pBluescript II KS (Strat-
agene). To construct the chimera clones, a BlnI restric-
tion site common to both WEE and EEE-cloned cDNA
and located 76 nucleotides downstream of the 26S pro-
moter region was used. The WEE nonstructural gene
region from either pWE1000 or pWE2000 was ligated to
the EEE structural gene region to form the chimeric
cDNA clones, pMWE1000 and pMWE2000, respectively.
The two chimeric clones were isogenic except for five
nucleotide changes in the first 25 nucleotides at their 5
termini (Fig. 2).
In vitro transcriptions and transfections
Plasmid DNA containing a full-length cDNA copy of
the viral RNA was linearized by restriction digestion at a
unique NotI site downstream of the poly(A) tract. Infec-
tious RNA was produced in runoff transcription reactions
as previously described (Rice et al., 1987) with modifica-
tions for T7 RNA polymerase. BHK-21 cells were trans-
fected with RNA by electroporation. Monolayers of
BHK-21 cells, 50–60% confluent, were trypsinized from
the culture flask surface, and the cells washed three
times in PBS, pH 7.4. The cell concentration was ad-
justed to 107 cells/ml in PBS. For each transfection, 0.8 ml
of cell suspension was placed in a 0.4-cm Gene Pulser
cuvette (Bio-Rad Laboratories, Hercules, CA); RNA tran-
scripts were added and electroporated. Electroporation
consisted of a Bio-Rad Gene Pulser II Apparatus (Bio-
Rad Laboratories) set at 0.85 kV and 25 Fd and deliv-
ering two pulses. Electroporated cells were held at room
temperature for 10 min and then transferred to a 75-cm2
cell culture flask containing 24 ml EMEM medium with
10% FBS. The transfected cells were incubated at 37°C
until cytopathic effect was evident.
Protein analysis
Structural proteins of chimeric and parental viruses
were analyzed by SDS–polyacrylamide gel electrophore-
sis (PAGE). Virions were concentrated by pelleting
through 20% sucrose cushion [wt/wt in TNE buffer (10
mM Tris–HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, pH
8.0)]. Pellets were resuspended by soaking overnight in
TNE buffer at 4°C. Immediately before electrophoresis,
virus was suspended in SDS–PAGE sample buffer and
boiled for 5 min. Virus structural proteins were resolved
by electrophoresis through a 10% polyacrylamide gel
containing SDS and visualized by staining with Coomas-
sie blue.
DNA sequencing
Plasmid DNA constructions or PCR products derived
from viral RNA were sequenced using virus-specific
primers with the PRISM Ready Reaction DyeOxy Termi-
nator Cycle Sequencing Kit (Applied Biosystems Divi-
sion, Perkin–Elmer Corp., Foster City, CA). Each nucleo-
tide was determined by sequencing both strands with an
ABI Model 373 Automated DNA Sequencer (Applied Bio-
systems Division, Perkin–Elmer). Sequence was edited,
aligned, and analyzed using the Inherit software package
(Applied Biosystems Division, Perkin–Elmer). The 5 ter-
minal sequence of the chimeric and parental viruses was
determined using the 5 RACE System (Gibco-BRL) as
described by the manufacturer. First-strand cDNA was
synthesized by using viral RNA as template for the Su-
perScript II RT. For WEE and EEE viruses, reverse prim-
ers WEns1962 (5-TCA CCT TAT TCT GGA ACA CAT
CAG-3) and E1886 (5-TCG GGG ATT GGT ATA GCT GTA
CC-3), respectively, were used for cDNA synthesis. After
dC-tailing of the cDNA, a PCR amplification of the 5
termini was performed using the Abridged Anchor Primer
and virus-specific primers, WEns559 (5-GGT AGA TTG
ATG TCG GTG CAT GG-3) for WEE and E618 (5-GGG
TAG GCG CCT GCC ATG TTC-3) for EEE. The PCR
products were purified on Wizard PCR Preps columns
and sequenced directly.
307WESTERN AND EASTERN EQUINE ENCEPHALITIS VIRUSES
One-step growth analysis
Growth curves for each virus were constructed by
infecting confluent monolayers of BHK-21 cells or C6/36
mosquito cells in 12-well plates (22-mm well) at a multi-
plicity of 5 in Hanks’ balanced salt solution (HBSS) con-
taining 1% fetal bovine serum (FBS). Virus and cells were
incubated for 1 h at the appropriate temperature, after
which the inoculum was removed and the cell monolay-
ers were washed three times with HBSS containing 1%
FBS. To BHK-21 cells, EMEM containing 5% FBS was
added and the cells were incubated at 37°C. To C6/36
cells, Singh mosquito culture medium containing 10%
FBS was added and the cells were incubated at 27°C.
Every hour postinfection, the cell culture fluid was re-
moved and fresh medium was added. Cell culture fluid
samples were assayed for virus by plaque assay on Vero
cell monolayers at 37°C.
RNA synthesis
Rates of RNA synthesis for each virus were deter-
mined in BHK-21 and C6/36 cells by infecting cells at a
multiplicity of 5 in HBSS containing 5% FBS. After 1 h
incubation at the appropriate temperature, the inoculum
was removed, washed three times with HBSS containing
1% FBS, and replaced with the appropriate medium con-
taining 5 g/ml actinomycin D. The concentration of
actinomycin D to inhibit host cell RNA synthesis in both
BHK-21 and C6/36 cells was previously determined by
assaying RNA synthesis of cells grown in media contain-
ing 1, 2, 4, 6, and 8 g/ml. It was found that host cell RNA
synthesis was inhibited by as little as 1 g/ml actinomy-
cin D (data not shown). After a 2 h incubation, 20 Ci/ml
of [3H]uridine was added to each well. At predetermined
time points, the culture fluid was removed and the cells
were washed with TNE buffer. The cells were scraped in
0.1 ml TNE buffer and each well was washed with an
additional 0.1 ml TNE buffer. SDS was added to the
supernatant to a final concentration of 1% and the radio-
labeled RNA was precipitated by adding an equal vol-
ume of 10% TCA (trichloroacetic acid) and incubated on
ice for 15 min. Precipitated RNA was collected on glass
filters, washed with 10% TCA and ethanol, and measured
by liquid scintillation counting.
Vaccination and challenge of mice
Five-week-old female mice (National Cancer Institute,
Frederick, MD) were inoculated subcutaneously with chi-
meric or parental viruses at doses of 103, 105, or 107 PFU
in 0.2 ml of HBSS diluent. Mock-vaccinated controls
received diluent alone. All mice were bled from the
retroorbital sinus under light anesthesia with Metafane
(Pitman-Moore, Mundelein, IL) 16 days p.i. to test for
virus-specific antibodies. Twenty-one days after vaccina-
tion, surviving mice were challenged with virulent virus
by intraperitoneal inoculation of 105 PFU of WEE virus
(Cba 87) or EEE virus (FL91-4679). The log10LD50 for WEE
and EEE challenge viruses were 2.0 and 2.3, respec-
tively. Therefore, the challenge dose of 105 PFU of Cba 87
and FL91-4679 viruses represented 912 and 525 mouse
LD50s, respectively. Twenty-one days after challenge,
surviving mice were bled for antibody analysis. Survival
rates were compared using Fisher’s exact test at the 95%
confidence level (SAS, 1996).
Antibody assays
Enzyme-linked immunosorbent assays (ELISA) utilized
gradient-purified WEE virus (Cba 87) or EEE virus (PE-6)
as antigen and horseradish peroxidase conjugated goat
anti-mouse immunoglobulin G as the reporter molecule.
Positive antibody controls were mouse polyclonal serum
against WEE virus (McMillian) or EEE virus (Alabama).
An optical density (450 nm) measurement of more than
three standard deviations above the mean background
absorbance (wells without serum) was scored as posi-
tive. Control mouse sera, postinoculation, and postchal-
lenge mouse sera were tested initially at a 1:100 dilution
and then at twofold dilutions to 1:204,800. Plaque reduc-
tion neutralization tests were performed on Vero cell
monolayers. Stock WEE virus (Cba 87) or EEE virus
(PE-6) was incubated with dilutions of serum overnight at
4°C. A standard plaque assay with the serum-treated
virus was performed on Vero cell monolayers. Virus and
cells were incubated for 1 h at 37°C and then overlaid
with 0.6% agarose and maintained for 24–48 h at 37°C.
Plaques were visualized by staining with neutral red.
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